ATE406896T1 - Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten - Google Patents

Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Info

Publication number
ATE406896T1
ATE406896T1 AT03713475T AT03713475T ATE406896T1 AT E406896 T1 ATE406896 T1 AT E406896T1 AT 03713475 T AT03713475 T AT 03713475T AT 03713475 T AT03713475 T AT 03713475T AT E406896 T1 ATE406896 T1 AT E406896T1
Authority
AT
Austria
Prior art keywords
dopamine
monoester
asymmetrically substituted
receptor agonist
agonist prodrugs
Prior art date
Application number
AT03713475T
Other languages
German (de)
English (en)
Inventor
Durk Dijkstra
Hakan Wikstrom
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Application granted granted Critical
Publication of ATE406896T1 publication Critical patent/ATE406896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03713475T 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten ATE406896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline

Publications (1)

Publication Number Publication Date
ATE406896T1 true ATE406896T1 (de) 2008-09-15

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03713475T ATE406896T1 (de) 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Country Status (11)

Country Link
US (1) US7220754B2 (enExample)
EP (1) EP1480647B1 (enExample)
JP (1) JP2005526728A (enExample)
AT (1) ATE406896T1 (enExample)
AU (1) AU2003217430B2 (enExample)
CA (1) CA2476115A1 (enExample)
DE (1) DE60323339D1 (enExample)
DK (1) DK1480647T3 (enExample)
ES (1) ES2314189T3 (enExample)
NO (1) NO20043634L (enExample)
WO (1) WO2003070245A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
CN1964713A (zh) * 2003-12-23 2007-05-16 达法尔摩公司 多巴胺-受体结合化合物的共同使用
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
EP2010541A2 (en) * 2006-02-21 2009-01-07 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
WO2014072881A1 (en) * 2012-11-08 2014-05-15 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282227A (en) 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine
PT690863E (pt) 1993-04-06 2003-07-31 Abbott Lab Compostos tetraciclicos como agonistas da dopamina
WO1996002513A1 (en) 1994-07-15 1996-02-01 Purdue Research Foundation Optically active isomers of dihydrexidine and its substituted analogs
PT845988E (pt) 1995-08-18 2002-05-31 Univ North Carolina Novas isoquinolinas fundidas como ligandos do receptor da dopamina

Also Published As

Publication number Publication date
EP1480647A4 (en) 2005-07-13
WO2003070245A1 (en) 2003-08-28
ES2314189T3 (es) 2009-03-16
JP2005526728A (ja) 2005-09-08
DK1480647T3 (da) 2009-01-26
AU2003217430A1 (en) 2003-09-09
AU2003217430B2 (en) 2008-10-23
DE60323339D1 (de) 2008-10-16
EP1480647B1 (en) 2008-09-03
WO2003070245B1 (en) 2004-05-27
CA2476115A1 (en) 2003-08-28
EP1480647A1 (en) 2004-12-01
US20050096469A1 (en) 2005-05-05
NO20043634L (no) 2004-11-11
US7220754B2 (en) 2007-05-22

Similar Documents

Publication Publication Date Title
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
CR9587A (es) Derivados de piridazina
PT1689387E (pt) Inibidores bicíclicos de mek e seus métodos de síntese
AR040870A1 (es) Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
MX2010007023A (es) Agonistas del receptor glucocorticoide sustituido de c20-c21.
ECSP045182A (es) Procedimiento para la preparación de ésteres de escopina
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
AR058296A1 (es) Inhibidores de histona desacetilasa y composicion farmaceutica
CO5590918A2 (es) Formulaciones
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
GB0604321D0 (en) Aminopyrones and their use as ATM inhibitors
AR016422A1 (es) Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento.
DE60323339D1 (de) Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
AR004512A1 (es) Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados
TW200745051A (en) 2-Phenylethylamino derivatives
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
CA2589438C (en) Treatment of inflammatory bowel disease
MY137868A (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation and ummunologically-mediated diseases
DE60222131D1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties